A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback

Motley Fool11-05 21:53

Idexx Laboratories benefits from operating in the resilient pet healthcare industry. The company's razor-and-blade business model adds a degree of stability for investors. Idexx is soon ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481838516?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795979%2Fgettyimages-530977027-5.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-11-05 21:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481838516","market":"fut","top_or_hot":-1,"title":"A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback","media":"Motley Fool","content":"<div>\n<p>Idexx Laboratories benefits from operating in the resilient pet healthcare industry.\n\n\n\n\n\n\n\nThe company's razor-and-blade business model adds a degree of stability for investors.\n\n\n\n\n\n\n\nIdexx is soon ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/11/05/once-in-a-decade-opportunity-1-super-sp-500-stock/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 21:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/11/05/once-in-a-decade-opportunity-1-super-sp-500-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Idexx Laboratories benefits from operating in the resilient pet healthcare industry.\n\n\n\n\n\n\n\nThe company's razor-and-blade business model adds a degree of stability for investors.\n\n\n\n\n\n\n\nIdexx is soon ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/11/05/once-in-a-decade-opportunity-1-super-sp-500-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4080","symbol_name":"零售业房地产投资信托","start_time":0,"source_url":"https://www.fool.com/investing/2024/11/05/once-in-a-decade-opportunity-1-super-sp-500-stock/","article_id":"2481838516","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795979%2Fgettyimages-530977027-5.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481838516","pubTimestamp":1730814780,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4080":"零售业房地产投资信托","BK4211":"区域性银行",".SPX":"S&P 500 Index","OEX":"标普100","BK4559":"巴菲特持仓","SPXU":"三倍做空标普500ETF","VOO":"Vanguard标普500ETF","BK4550":"红杉资本持仓","BK4588":"碎股","OEF":"标普100指数ETF-iShares","SSO":"两倍做多标普500ETF","ROIC":"Retail Opportunity Investments C","BK4231":"零售房地产信托","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF","BK4581":"高盛持仓","BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","IVV":"标普500指数ETF","SH":"标普500反向ETF","FCF":"第一联邦金融","SPY":"标普500ETF","BK4585":"ETF&股票定投概念"},"translate_title":"十年一遇的机会：1只超级标普500股票在近期回调后下跌40%值得买入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOO":1,"SPY":1,"ROIC":1,"FCF":1,".SPX":1,"ESmain":0.6,"UPRO":0.6,"SSO":0.6,"SPXU":0.6,"SH":0.6,"SDS":0.6,"OEX":0.6,"OEF":0.6,"IVV":0.6},"content_text":"Idexx Laboratories benefits from operating in the resilient pet healthcare industry.\n\n\n\n\n\n\n\nThe company's razor-and-blade business model adds a degree of stability for investors.\n\n\n\n\n\n\n\nIdexx is soon to expand into oncology screening and also has a quickly growing software business.\n\nWhile the debate over whether it's better to pay for high-quality or high-growth businesses will never end, the easiest solution is to find stocks offering both.One company that fits this best-of-both-worlds billing is Idexx Laboratories (IDXX -0.29%), offering leading pet healthcare diagnostics operations. Delivering annualized revenue and free-cash-flow growth of 10% and 25%, respectively, over the past decade, the company's razor-and-blade model has turned it into a steady compounder.Idexx Labs has a wide array of solutions that help keep pets happy and healthy, ranging from point-of-care diagnostic equipment and rapid assay tests to reference lab guidance, consulting services, and veterinary software. Thanks to this suite of solutions, the company has become a leader in its $45 billion pet healthcare diagnostics niche. However, after experiencing a boom during the pandemic as pet adoptions ballooned, Idexx has struggled to get its sales growth back to its old double-digit mark, registering 7% growth in its most recent quarter.  Due to this combination of decelerating growth and the company's once-lofty valuation, Idexx's share price has dropped 40% from its all-time highs in 2021.But there may be better days ahead. With the shares now trading at their most reasonable valuation in almost a decade, here are four reasons why Idexx is one of the most compelling S&P 500 stocks to buy right now.1. The durable pet healthcare industryTypically, the pet care industry is as resilient as any industry can be, barring pandemic-aided boom-and-bust cycles. In a recent 2024 study on spending, only 4% of pet parents stated that they delayed a sick visit to the vet's office, whereas 21% of respondents had delayed a vacation, and 44% had reduced their spending on eating out.And this is not a one-year phenomenon. Over the past decade, the average lifespan of dogs and cats has risen by 1.4 years and 1.9 years, respectively, highlighting the ever-growing pet-human bond. This bond between humans and their furry friends is even stronger among younger millennial and Gen Z pet parents, who are more likely to agree to annual pet wellness exams.Buoyed by this long-term megatrend, Future Market Insights believes the vet diagnostics market will grow by 10% annually through 2034, while Idexx itself estimates a 9% growth rate is possible through 2048. Image source: Getty Images.2. Idexx's razor-and-blade business modelIn addition to operating in a resilient market, Idexx's razor-and-blade business model provides additional stability for investors. With an installed base of over 144,000 diagnostics instruments -- up 10% from last year -- Idexx has a truly global presence.Despite this massive installed base of equipment, management believes it could still double these placements over the long term as it dives deeper into international markets.However, what makes this equipment important to investors is that it sets the stage for what really drives Idexx's performance -- recurring sales from vet lab consumables (such as test cartridges), reference lab diagnostics, and consulting services. These high-margin, recurring revenue streams account for 80% of Idexx's sales, making the company a durable investment proposition.3. Expanding growth optionalityWhile the company's current operations are promising enough, its developments in oncology and software could spur a new wave of growth. Expanding upon its current cytology, hematology, and urine analysis solutions (among many more), Idexx plans to launch a suite of oncology products in Q4 2024 and 2025.Within the next three years, management believes it will be able to expand its panel to detect over 50% of canine cancer cases, enabling earlier detection and better treatment options.In addition to this promising growth area, Idexx is building out its full suite of veterinary software that covers everything from pet-owner engagement to payments and digital workflows at the vet office. Already home to an industry-leading customer satisfaction score, the company's software solutions have grown by 15% annually since 2019, with recurring revenue in the unit growing even faster at 23%. 4. Idexx's once-in-a-decade valuationAlthough Idexx isn't trading at a \"traditionally cheap\" valuation, at 42 times free cash flow (FCF), its current price-to-FCF ratio is the lowest it has been since 2016.IDXX Price to Free Cash Flow data by YChartsWhile this valuation remains a premium to the S&P 500's average P/FCF of roughly 32, I'd argue that Idexx and its razor-and-blade model, durable industry, and growth optionality make it one of the better stocks in the index and worthy of this valuation.Home to a return on invested capital (ROIC) of 38% -- the 19th highest in the S&P 500, which is a historical indicator for outperformance potential -- Idexx looks like a fantastic buying opportunity following its recent 40% pullback.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481838516"}